Oncolytics Biotech (ONCY) Stock Analysis

What Oncolytics Biotech does

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Key metrics

ETFs linked to ONCY

Broad-market and Healthcare sector ETFs an investor holding Oncolytics Biotech is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ONCY fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Oncolytics Biotech?

Oncolytics Biotech trades under the ticker ONCY on NASDAQ.

Which exchange is ONCY listed on?

ONCY is listed on NASDAQ.

What sector does Oncolytics Biotech operate in?

Oncolytics Biotech is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ONCY in a portfolio?

PortView shows ONCY's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.